Renal Data

Less impact on markers of renal function across populations

DESCOVY® had less long-term impact on markers of renal function over 96 weeks vs FTC/TDF1,2

Median change in eGFRCG through Week 96

There was a 3.5-mL/min difference between DESCOVY FOR PrEP (-0.6 mL/min) and FTC/TDF (-4.1 mL/min) in eGFRCG at Week 96.

The long-term clinical significance of changes in eGFR is not known.

Lower serum creatinine levels were also seen with DESCOVY FOR PrEP through Week 96

  • Mean serum creatinine increased 0.01 mg/dL with DESCOVY FOR PrEP vs a 0.03-mg/dL increase with FTC/TDF from baseline at Week 96

Switching to DESCOVY® resulted in increased eGFR vs FTC/TDF through Week 961,2

Median change in eGFRCG

There was a 5.6-mL/min difference between DESCOVY FOR PrEP (+3.0 mL/min) and FTC/TDF (-2.6 mL/min) in eGFRCG at Week 96.

The long-term clinical significance of changes in eGFR is not known.

DESCOVY® had less long-term impact on eGFR over 96 weeks in patients ≥50 years of age1-4

Results were seen in patients of an age group that may already be experiencing age-associated declines

Median change in eGFRCG in patients ≥50 years of age

There was a 4.4-mL/min difference between DESCOVY FOR PrEP (-1.1 mL/min) and FTC/TDF (-5.5 mL/min) in eGFRCG at Week 96.

The long-term clinical significance of changes in eGFR is not known.

DESCOVY FOR PrEP® can be used in patients with impaired renal function of CrCl ≥30 mL/min.1

eGFRCG=estimated glomerular filtration rate (Cockcroft-Gault); FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; Q1, Q3=first quartile, third quartile.